Searching the ideal inhaled vasodilator: From nitric oxide to prostacyclin

European Surgical Research

Volumn 34, Issue 1-2, 2002, Pages 196-202

  Kemming, Gregor ^a,b,d   Habler, O ^a,b   Kleen, M ^a,b   Kisch Wedel, H ^a,b   Welte, M ^a,c   Zwissler, B ^a,b  

^a Institute for Surgical Research   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Inhaled nitric oxide and prostacyclin; Jet nebulizer; Pulmonary hypertension; Pulmonary vasodilation

Indexed keywords

BERAPROST; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; UNIPROST; VASODILATOR AGENT;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG BLOOD VESSEL; LUNG GAS EXCHANGE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATATION;

ADMINISTRATION, INHALATION; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; NEBULIZERS AND VAPORIZERS; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 0036184483     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048909     Document Type: Article

References (114)

1. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension
2. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
3. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
4. 2-aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction
5. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction
6. Effects of inhaled prostacyclin as compared with inhaled nitric oxide in a canine model of pulmonary microembolism and oleic acid edema
7. Prostacyclin aerosol and inhaled nitric oxide fail to reverse pulmonary vasoconstriction induced by thromboxane analogue in dogs
8. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass
9. 2) in healthy lambs: Effects on tracheal, bronchial, and alveolar morphology
10. 2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs
11. Inhaled sodium nitroprusside. Non-selective reduction of thromboxane analogue-induced pulmonary vasoconstriction in healthy sheep
12. 2) versus inhaled nitric oxide in adult respiratory distress syndrome
13. Aerosol production and aerosol droplet size distribution during mechanical ventilation (IPPV) with a new ultrasonic nebulizer
14. Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation
15. Efficacy of inhaled prostanoids in experimental pulmonary hypertension
16. Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury
17. Inhalation of selective pulmonary vasodilators: Effects on myocardial contractility
18. The increased left ventricular contractility by the prostacyclin analogue epoprostenol is mediated by cyclic adenosine monophosphate (cAMP)
19. 2) increases left ventricular contractility in vivo
20. Administration of therapeutic aerosols to mechanically ventilated patients
21. Trials of inhaled iloprost and other new vasodilating prostaglandins
22. Nitric oxide: Physiology, pathophysiology, and pharmacology
23. The 1991 Ulf von Euler Lecture. The L-arginine:nitric oxide pathway
24. Effects of endogenous nitric oxide on the pulmonary circulation
25. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease
26. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: Dose response
27. Inhaled nitric oxide selectively decreases pulmonary vascular resistance without impairing oxygenation during one-lung ventilation in patients undergoing cardiac surgery
28. Nitric oxide and the lung
29. Inhaled nitric oxide in acute respiratory failure
30. Inhaled nitric oxide therapy
31. Inhalation of vasodilatory drugs or gases
32. Use of inhaled nitric oxide perioperatively and in intensive care patients
33. Sites of inhaled NO-induced vasodilation during hypoxia and U-46619 infusion in isolated lamb lungs
34. Inhaled nitric oxide partially reverses hypoxic pulmonary vasoconstriction in the dog
35. Treatment of acute pulmonary hypertension with inhaled nitric oxide
36. Inhaled nitric oxide in congenital diaphragmatic hernia
37. Efficacy of inhaled nitric oxide in patients with severe ARDS
38. Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance
39. Changes in pulmonary vascular tone during exercise. Effects of nitric oxide (NO) synthase inhibition, L-arginine infusion, and NO inhalation
40. Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury
41. Inhaled nitric oxide: Selective pulmonary vasodilation in cardiac surgical patients
42. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: A dose-response study and comparison with prostacyclin
43. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome
44. Inhaled nitric oxide improves hepatic tissue oxygenation in right ventricular failure: Value of hepatic venous oxygen saturation monitoring
45. Inhaled nitric oxide in patients with normal and increase pulmonary vascular resistance after cardiac surgery
46. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
47. Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits
48. Increased nitric oxide in exhaled gas as an early marker of lung inflammation in a model of sepsis
49. Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx
50. Nitric oxide (NO) in expired air at rest and during exercise
51. Inhaled nitric oxide: State of the art
52. Inhaled Nitric oxide
53. Inhaled nitric oxide (NO): A concise review
54. Inhaled nitric oxide, clinical rationale and applications
55. Inhaled nitric oxide
56. The biology of nitrogen oxides in the airways
57. Acute lung injury and inhaled NO. The reduction of pulmonary capillary pressure has implications for lung fluid balance
58. Bleeding time prolongation and NO inhalation
59. Prolonged bleeding time during nitric oxide inhalation in the rabbit
60. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension
61. The pharmacology of inhaled nitric oxide
62. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation
63. Inhaled nitric oxide in neonates and children with pulmonary hypertension
64. Effect of methylene blue on the vasodilator action of inhaled nitric oxide in hypoxic sheep
65. DNA damage and mutation in human cells exposed to nitric oxide in vitro
66. Mutations induced by saturated aqueous nitric oxide in the pSP189 supF gene in human Ad293 and E coli MBM7070 cells
67. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs
68. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome
69. Inhaled nitric oxide: Technical aspects of administration and monitoring
70. Guidelines for the safe administration of inhaled nitric oxide
71. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension
72. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients
73. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction
74. Hemodynamic effects of inhaled nitric oxide in heart failure
75. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure
76. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial
77. Pharmacodynamic profile of prostacyclin
78. Cloning and expression of a cDNA for the human prostacyclin receptor
79. Inhalational agents for pulmonary hypertension
80. Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator
81. Aerosolised prostacyclin in adult respiratory distress syndrome
82. 2) in acute respiratory failure with pulmonary hypertension in piglets
83. Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension
84. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension
85. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension
86. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
87. Effect of inhaled prostacyclin in combination with almitrine on ventilation-perfusion distributions in experimental lung injury
88. Aerosolised prostacyclin for pulmonary hypertension in neonates
89. Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure
90. Prostacyclin aerosol in an infant with pulmonary hypertension
91. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome
92. Hämodynamische effekte von epoprostenol als aerosol zur selektiven pulmonalen vasodilatation versus intravenöser applikation nach kardiochirurgischer intervention
93. Effects of aerosolized prostacyclin in severe pneumonia: Impact of fibrosis
94. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms
95. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation
96. Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled aerosolized prostacyclin
97. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
98. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response
99. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system
100. Effect of diaphragm contraction on canine heart and pericardium
101. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
102. Pulmonary deposition of a nebulised aerosol during mechanical ventilation
103. Aerosol deposition in mechanically ventilated patients
104. Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery
105. Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man
106. Effect of low concentrations of prostacyclin on platelet function in vitro
107. Systemic levels of 6-ketoprostaglandin F-1 alpha following administration of inhaled aerosolized prostacyclin
108. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
109. Long-term treatment of pulmonary hypertension with aerosolized iloprost
110. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
111. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension
112. Long-term treatment of pulmonary hypertension with aerosolized iloprost
113. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis
114. Long-term treatment of primary pulmonary hypertension with inhaled iloprost